Abstract: The targeting of checkpoint inhibitors in colorectal cancer (CRC) has concentrated on the subset of tumors with high Microsatellite Instability (MSI). Moreover, MSI or mismatch repair (MMR) testing is not part of the routine clinical workup for all tumors despite potential for successful immunotherapy, because the results are not consistent for most cancer types outside of colorectal and endometrial cancer. In certain cancer types, tumors with MSI often have high Tumor Mutation Burden (TMB) in addition to the subset which can have high TMB and are Microsatellite Stable. Herein, we report the results of testing for MSI, Tumor Mutation Burden (TMB), and for mutations in MMR genes and other cancer biomarkers to understand the associations in multiple cancer types.
Please fill out the short form below to access the poster.